Targeting pathogenic T helper cell memory

Annals of the Rheumatic Diseases

Volumn 70, Issue SUPPL. 1, 2011, Pages

  Chang, Hyun Dong ^a   Radbruch, Andreas ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CD52 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; RITUXIMAB; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; TWIST1 PROTEIN, HUMAN;

AUTOIMMUNITY; BONE MARROW; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; CONFERENCE PAPER; EFFECTOR CELL; HELPER CELL; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; TH1 CELL; TH17 CELL; CELL LINEAGE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; GENE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LYMPHOCYTE SUBPOPULATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; TARGET CELL; TARGET CELL DESTRUCTION; TWIST1 GENE; AUTOIMMUNE DISEASE; BONE MARROW CELL; CHRONIC DISEASE; IMMUNOLOGY; INFLAMMATION; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW;

AUTOIMMUNE DISEASES; BONE MARROW CELLS; CHRONIC DISEASE; HUMANS; IMMUNOLOGIC MEMORY; INFLAMMATION; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TWIST TRANSCRIPTION FACTOR;

EID: 79953002193     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.140954     Document Type: Conference Paper

References (49)

1. Löhning M, Richter A, Radbruch A. Cytokine memory of T helper lymphocytes. Adv Immunol 2002;80:115-81. (Pubitemid 34625622)
2. Lexberg MH, Taubner A, Förster A, et al. Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol 2008;38:2654-64.
3. Hegazy AN, Peine M, Helmstetter C, et al. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 and Th1 cell functions. Immunity 2010;32:116-28.
4. Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009;30:92-107.
5. Kohem CL, Brezinschek RI, Wisbey H, et al. Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:844-54.
6. Thomas R, McIlraith M, Davis LS, et al. Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. Arthritis Rheum 1992;35:1455-65. (Pubitemid 23013653)
7. Nanki T, Lipsky PE. Cytokine, activation marker, and chemokine receptor expression by individual CD4(+) memory T cells in rheumatoid arthritis synovium. Arthritis Res 2000;2:415-23. (Pubitemid 32223780)
8. Infante-Duarte C, Horton HF, Byrne MC, et al. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000;165:6107-15.
9. Aarvak T, Chabaud M, Miossec P, et al. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999;162:1246-51. (Pubitemid 29306992)
10. Chabaud M, Aarvak T, Garnero P, et al. Potential contribution of IL-17-producing Th(1) cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions. Cytokine 2001;13:113-8. (Pubitemid 32579318)
11. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268:1185-8.
12. Iqbal N, Oliver JR, Wagner FH, et al. T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 2002;195:71-84. (Pubitemid 34074498)
13. Maffia P, Brewer JM, Gracie JA, et al. Inducing experimental arthritis and breaking self-tolerance to joint-specific antigens with trackable, ovalbumin-specific T cells. J Immunol 2004;173:151-6. (Pubitemid 38797336)
14. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40. (Pubitemid 40189432)
15. Thakker P, Leach MW, Kuang W, et al. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007; 178:2589-98. (Pubitemid 46233462)
16. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7. (Pubitemid 38032126)
17. O'Connor RA, Prendergast CT, Sabatos CA, et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008;181:3750-4.
18. Annunziato F, Cosmi L, Liotta F, et al. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009;5:325-31.
19. Boniface K, Blumenschein WM, Brovont-Porth K, et al. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol 2010;185:679-87.
20. Kebir H, Ifergan I, Alvarez JI, et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009;66:390-402.
21. Skurkovich S, Boiko A, Beliaeva I, et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler 2001; 7:277-84. (Pubitemid 33026252)
22. Ryan C, Thrash B, Warren RB, et al. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10:587-604.
23. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53.
24. Sattler A, Wagner U, Rossol M, et al. Cytokine-induced human IFN-gamma-secreting effector-memory Th cells in chronic autoimmune inflammation. Blood 2009;113:1948-56.
25. Gershon RK, Paul WE. Effect of thymus-derived lymphocytes on amount and affinity of anti-hapten antibody. J Immunol 1971;106:872-4.
26. Francus T, Francus Y, Siskind GW. Memory T cells enhance the expression of highavidity naive B cells. Cell Immunol 1991;134:520-7.
27. Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003;171:4969-73. (Pubitemid 37432774)
28. Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004;199:1577-84. (Pubitemid 38780412)
29. van der Lubbe PA, Dijkmans BA, Markusse HM, et al. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
30. Breedveld FC. Monoclonal antibodies to CD4. Rheum Dis Clin North Am 1998;24:567-78. (Pubitemid 28416809)
31. Horneff G, Burmester GR, Emmrich F, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129-40.
32. Horneff G, Emmrich F, Reiter C, et al. Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. J Rheumatol 1992;19:1845-50. (Pubitemid 23018514)
33. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995;38:1589-94.
34. Isaacs JD, Manna VK, Rapson N, et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 1996;35:231-40.
35. Brett S, Baxter G, Cooper H, et al. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996;88:13-9.
36. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009;113:214-23.
37. Finnegan A, Schnitzer TJ. Persistence of CD4+ T cells in the arthritic joint after CAMPATH-1H treatment. J Rheumatol 1997;24:1448-9. (Pubitemid 27353397)
38. Jendro MC, Ganten T, Matteson EL, et al. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum 1995;38:1242-51.
39. Niesner U, Albrecht I, Janke M, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008;205:1889-901.
40. Connerney J, Andreeva V, Leshem Y, et al. Twist1 dimer selection regulates cranial suture patterning and fusion. Dev Dyn 2006;235:1345-57. (Pubitemid 43843917)
41. Bell EB, Westermann J. CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol 2008;29:405-11.
42. van Leeuwen EM, Sprent J, Surh CD. Generation and maintenance of memory CD4(+) T Cells. Curr Opin Immunol 2009;21:167-72.
43. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med 1991;174:969-74.
44. Kondrack RM, Harbertson J, Tan JT, et al. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 2003;198:1797-806. (Pubitemid 38032113)
45. Lenz DC, Kurz SK, Lemmens E, et al. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci USA 2004;101:9357-62. (Pubitemid 38812880)
46. Tokoyoda K, Zehentmeier S, Hegazy AN, et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 2009;30:721-30.
47. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009;5:433-41.
48. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55. (Pubitemid 351951516)
49. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008;180:361-71.